Literature DB >> 6450078

Impaired concanavalin A-inducible suppressor T-cell activity in active alcoholic liver disease.

H Kawanishi, H Tavassolie, R P MacDermott, J N Sheagren.   

Abstract

To examine the possible contribution of cellular immunoregulatory mechanisms to the pathogenesis and progression of alcoholic liver diseases, suppressor T-cell function was evaluated in patients with severe active or inactive alcoholic liver disease and compared with normal control subjects. Suppressor T-cell activity after in vitro induction by concanavalin A or other T cell-mediated immune reactions was then assessed. T-cell interactions studied included the proliferative responses of both autologous or allogeneic responding peripheral blood mononuclear cells to T-cell mitogens and to allogeneic cells. No significant differences were found in the ability to induce suppressor T cells between controls and patients with inactive alcoholic liver disease (p < 0.05). In contrast, T cells from patients with severe active alcoholic liver disease failed to develop suppressor cell activity (p < 0.001) after concanavalin A stimulation; restoration of suppressor cell function was found after these patients improved clinically. Adherent cells (monocyte-macrophages) from patients with active alcoholic liver diseases exhibited normal support of concanavalin A-induced blastogenesis and suppressor T-cell generation. This immunoregulatory cell abnormality could be important in the pathogenesis and/or progression of active alcoholic liver disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6450078

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  15 in total

1.  Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage.

Authors:  W L Chuang; H W Liu; W Y Chang; S C Chen; M Y Hsieh; L Y Wang
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

2.  In vitro induction of a contrasuppressor immunoregulatory network by polyclonally activated T cells derived from murine Peyer's patches.

Authors:  H Kawanishi; J Kiely
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

3.  Alcoholic cirrhosis patients and HIV infection.

Authors:  C Buffet; H Champsaur; M German-Fattal; T Lambert; M J Briantais; J P Etienne
Journal:  Dig Dis Sci       Date:  1988-08       Impact factor: 3.199

4.  Suppressor T cell activity and antibodies to alcohol altered hepatocytes.

Authors:  F Pons Romero; S Echevarria; C Rodriguez de Lope; G San Miguel
Journal:  J Clin Pathol       Date:  1984-05       Impact factor: 3.411

5.  Immunoglobulin production by peripheral blood mononuclear cells in patients with alcoholic liver disease.

Authors:  M A Rodriguez; J D Montano; R C Williams
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

6.  Deficient natural killer cell activity in alcoholic cirrhosis.

Authors:  B Charpentier; D Franco; L Paci; M Charra; B Martin; D Vuitton; D Fries
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

7.  Correction of a suppressor cell deficiency in four patients with familial Mediterranean fever by in vitro or in vivo colchicine.

Authors:  D Ilfeld; O Kuperman
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

8.  Decreased proliferative activity associated with activation markers in patients with alcoholic liver cirrhosis.

Authors:  J Devière; C Denys; L Schandene; F Romasco; M Adler; J Wybran; E Dupont
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

9.  In vitro correction of a deficiency of Con A-induced suppressor cell function in primary biliary cirrhosis by a pharmacological concentration of colchicine.

Authors:  D Ilfeld; E Theodor; G Delpre; O Kuperman
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

10.  Demonstration of non-specific B-cell stimulation in patients with cirrhosis.

Authors:  G Holdstock; W B Ershler; E L Krawitt
Journal:  Gut       Date:  1982-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.